Microcapsules based on functional oligosaccharides, probiotics, and their metabolites, their preparation method, and applications

By using a three-layer composite microcapsule design and precise pairing of functional oligosaccharides and probiotics, the problems of low survival rate and poor stability of synergistic effects in probiotic products have been solved, achieving the effect of quickly relieving intestinal flora imbalance and mood disorder.

CN123100831APending Publication Date: 2026-11-17EAST CHINA UNIV OF SCI & TECH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202611304436.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-26
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current probiotic products suffer from low probiotic survival rates, slow onset of action, and poor stability of sugar-bacteria synergistic effects, making it difficult to effectively regulate gut microbiota and address mood imbalances.

Method used

The microcapsule design employs a three-layer composite structure, consisting of a probiotic powder core, a functional oligosaccharide-yeast protein combination coating, and a functional small molecule metabolite complex enteric coating. It utilizes different release mechanisms to achieve preferential release of metabolites in the upper and middle segments of the small intestine and delayed release of probiotics in the colon. Combined with the precise pairing of functional oligosaccharides and probiotics, it forms a relay metabolism between strains.

Benefits of technology

It achieves rapid colonization of probiotics in the gut and continuous release of metabolites, quickly relieves acute stress, regulates mood in the long term, significantly increases butyrate production and mood improvement, and improves probiotic survival rate and synergistic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123100831A_ABST
    Figure CN123100831A_ABST
Patent Text Reader

Abstract

This invention relates to a microcapsule based on functional oligosaccharides, probiotics, and their metabolites, its preparation method, and its application. The microcapsule comprises, from the inside out, a probiotic powder core, a functional oligosaccharide-yeast protein composite coating, and a functional small molecule metabolite complex enteric coating. The probiotic powder core is prepared from lyophilized probiotic powder, low-esterified pectin, and sodium alginate. The functional oligosaccharide-yeast protein composite coating is prepared from functional oligosaccharides and yeast protein. The functional small molecule metabolite complex enteric coating is prepared from lyophilized functional small molecule metabolite complex powder, pH-sensitive enteric material, and plasticizer. The lyophilized functional small molecule metabolite complex powder exists in the form of a functional small molecule metabolite-resistant dextrin complex. Compared with existing technologies, this invention provides a novel option for individuals with intestinal flora imbalance, emotional imbalance, and psychological stress through sequential delivery, specific sugar-bacteria synergy, and targeted feeding of specific bacterial groups.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of functional food technology, and in particular to a microcapsule based on functional oligosaccharides-probiotics and their metabolites, its preparation method and application. Background Technology

[0002] The fast pace of modern life, chronic stress, and dietary imbalances can easily lead to gut microbiota imbalance, which in turn affects the function of the central nervous system through the gut-brain axis, inducing psychological problems such as anxiety, depression, mood swings, and stress responses. Statistics show that a significant proportion of adults in my country suffering from anxiety and depression have symptoms closely related to gut microbiota dysbiosis. Furthermore, gut microbiota dysbiosis is often accompanied by increased intestinal mucosal permeability, allowing lipopolysaccharide (LPS) endotoxins produced by Gram-negative bacteria in the gut to enter the bloodstream. LPS can induce systemic low-grade inflammation and cross the blood-brain barrier to activate microglia, triggering neuroinflammation. This, in turn, interferes with the synthesis and metabolism of neurotransmitters such as serotonin (5-HT) and dopamine, inducing or exacerbating anxiety, depression, and stress responses.

[0003] Given that traditional drug treatments often involve side effects such as weight gain, cognitive impairment, and even drug dependence, current research is increasingly focusing on the interaction mechanisms of the diet-gut microbiota-brain axis, aiming to regulate mood and improve sleep through dietary strategies. Among these, prebiotics (mainly functional oligosaccharides) and probiotics can improve mood and sleep by improving gut microbiota structure, increasing the secretion levels of specific substances, and regulating neuroendocrine and immune functions. Therefore, improving mood through gut microbiota regulation has become a research hotspot in the field of functional foods.

[0004] Currently, drugs / foods used to improve mood are mainly divided into the following categories: (1) Chemical drugs that act directly on the central nervous system, such as 5-HT reuptake inhibitors (SSRIs). These drugs exert anti-anxiety and anti-depressant effects by regulating neurotransmitter levels. Although the efficacy is certain, there are side effects such as nausea, insomnia, and weight gain. Long-term use may also lead to drug dependence, which is not suitable for long-term use by sub-healthy people; (2) Probiotic preparations, which regulate the intestinal flora by supplementing specific strains, but there are problems such as low survival rate of probiotics and weak specificity of strains in regulating mood; (3) Prebiotic products, which promote the proliferation of beneficial bacteria by supplementing functional oligosaccharides, but lack direct supplementation of probiotics, and the mood regulation effect is not obvious; (4) Probiotic-prebiotic preparations, which combine the two, but the synergy between probiotics and prebiotics is poor, and the mood regulation effect is unstable.

[0005] CN116555129A discloses a strain of Lactobacillus gasseri BDUP, its applications, and products. This strain can produce high levels of GABA (γ-aminobutyric acid) under culture conditions without the addition of glutamate and can improve depressive-like behavior in mice. It can be used for probiotic treatment of stress-related mood disorders such as depression and insomnia. However, this product only involves the probiotic itself, and its mood-improving effect is limited.

[0006] CN105073120A discloses the use of a galactooligosaccharide composition for the prevention or treatment of cognitive impairment and mood disorders in neuropsychiatric diseases or aging. Animal experiments show that it can reduce cortisol secretion and has anti-anxiety properties. However, this approach only involves a single oligosaccharide component, and its mechanism of action depends on the patient's own gut microbiota's utilization of GOS, thus having limited improvement effects on patients with severe gut microbiota dysbiosis.

[0007] CN117887646A discloses a compound probiotic for anti-anxiety and anti-depression and its application, using a combination of *Weizmannii coagulans* BC99 and *Bifidobacterium bifidum* BBi32. Animal experiments showed that it could reduce anxiety and depression-like behaviors in mice and regulate the levels of neuroprotective factors and intestinal metabolites. However, this scheme only involves the compounding of probiotics and lacks probiotic encapsulation technology. The survival rate of the strains in the acidic environment of the stomach is low, thus limiting the effect on mood improvement.

[0008] CN114304513A discloses an oral compound bacterial fermentation product and its application, comprising fermentation products from multiple bacterial strains, capable of acting on the gut-mouth-skin axis to promote the conversion of neurotransmitters for mood repair and aid in mood regulation. However, this approach only involves fermentation products and cannot achieve intestinal colonization of probiotics, nor does it address the specific pairing of bacterial strains with functional oligosaccharides, making it difficult to achieve rapid and lasting mood improvement effects.

[0009] Therefore, in view of the technical problems of existing probiotic products, such as low probiotic survival rate, slow onset of action, and poor stability of sugar-bacteria synergistic effect, it is still necessary to develop a new type of probiotic functional food that is more suitable for sub-healthy people to regulate intestinal microecology and regulate daily mood. Summary of the Invention

[0010] The purpose of this invention is to overcome at least one defect of the prior art and provide a microcapsule based on functional oligosaccharides, probiotics and their metabolites, as well as its preparation method and application.

[0011] The objective of this invention can be achieved through the following technical solutions: The first aspect of the present invention provides a microcapsule based on functional oligosaccharides-probiotics and their metabolites, wherein the microcapsule comprises, from the inside out, a probiotic powder core, a functional oligosaccharide-yeast protein combination coating, and a functional small molecule metabolite complex enteric coating.

[0012] The probiotic powder core is prepared from probiotic freeze-dried powder, low-ester amidated pectin, and sodium alginate in a mass ratio of (15~25): (10~16): (1~2); wherein, the probiotic freeze-dried powder is selected from... Anaerobutyricum soehngenii , Coprococcus comesus , Lachnoclostridium phocaeense One or more of the following, the total colony count in the probiotic freeze-dried powder is not less than 1.0 × 10⁻⁶. 8 CFU / g.

[0013] The functional oligosaccharide-yeast protein combination coating is prepared by using functional oligosaccharide and yeast protein in a mass ratio of (15~25): (10~15); wherein the functional oligosaccharide is one or more of neo-agnatase, 2'-FL, xylotriose, chitobiose, and maltotetraose.

[0014] The functional small molecule metabolite complex enteric coating is prepared by using a functional small molecule metabolite complex lyophilized powder, a pH-sensitive enteric coating material, and a plasticizer in a mass ratio of (10~20): (10~16): (1~4); wherein the functional small molecule metabolite complex lyophilized powder exists in the form of a functional small molecule metabolite-resistant dextrin complex, and the functional small molecule metabolite is one or more of propionic acid, butyric acid, 3,4-dihydroxyphenylacetic acid, 5-hydroxytryptamine, phenyllactic acid, indoleacetic acid, and indolelactic acid.

[0015] Furthermore, the coating thickness of the functional oligosaccharide-yeast protein combination is 10~15μm.

[0016] Furthermore, the thickness of the enteric coating of the functional small molecule metabolite complex is 8~14 μm.

[0017] Furthermore, the overall diameter of the microcapsule is 120~180 μm.

[0018] Furthermore, the probiotic powder core, the functional oligosaccharide-yeast protein combination coating, and the functional small molecule metabolite complex enteric coating account for 45%~55%, 30%~35%, and 15%~25% of the total mass of the microcapsules, respectively.

[0019] Furthermore, the degree of esterification of the low-ester amidated pectin is not higher than 50%.

[0020] Furthermore, the degree of amidation of the low-ester amidated pectin is 20% to 35%.

[0021] Furthermore, the low-ester amidated pectin can be specifically degraded by pectinase secreted by colonic flora.

[0022] Furthermore, the probiotic freeze-dried powder is Anaerobutyricum soehngenii , Coprococcus companion and Lachnoclostridium phocaeense The compound has a mass ratio of (15~25): (10~15): (5~10).

[0023] Furthermore, the probiotic freeze-dried powder is prepared by the following method: the target strain is inoculated onto a solid culture medium and cultured anaerobically at 37 °C for 48–72 hours; single colonies are picked for purification culture; the purified single colonies are inoculated into a liquid culture medium and cultured anaerobically at 37 °C for 24–36 hours to obtain a seed culture; the seed culture is inoculated into a fermenter at an inoculation rate of 5%–10% and fermented anaerobically at 37 °C for 24–48 hours until the viable probiotic count reaches 1.0 × 10⁻⁶. 8 ~1.0×10 9 CFU / mL, collect bacterial sludge by centrifugation; mix bacterial sludge with pre-cooled compound freeze-drying protectant at a mass ratio of 1: (2~3), freeze-dry after pre-freezing, grind and pulverize, and sieve to obtain probiotic freeze-dried powder.

[0024] Furthermore, the composite freeze-drying protectant is composed of the following raw materials in the indicated mass percentages: 10%~20% skim milk powder, 5%~10% trehalose, 0.8%~1.2% monosodium glutamate, 0.4%~0.6% cysteine ​​hydrochloride, and the remainder being sterile water.

[0025] Furthermore, the functional oligosaccharide is a compound of neo-agnatase, 2'-FL, xylotriose, chitobiose, and maltotetraose, with a mass ratio of (15~35):(8~20):(5~20):(3~5):(3~15).

[0026] Furthermore, the yeast protein is a protein hydrolysate obtained by controlled enzymatic hydrolysis of Saccharomyces cerevisiae, and its peptide molecular weight is mainly distributed between 5000 and 30000 Da.

[0027] Furthermore, the resistant dextrin is one or more of the following: high-branched corn starch-based water-soluble resistant dextrin with a DE value of 3-6, esterified resistant dextrin, and cassava-based resistant dextrin with a DE value of 6-10.

[0028] Furthermore, the pH-sensitive enteric material is Eudragit L30D-55 aqueous dispersion.

[0029] Furthermore, the plasticizer is triethyl citrate.

[0030] Furthermore, the mass ratio of the functional small molecule metabolite to resistant dextrin is 1:(2~4).

[0031] Furthermore, the functional small molecule metabolites are prepared by the following method: probiotics are inoculated into a fermentation medium containing functional oligosaccharides at a total inoculum of 5% to 10%, and the amount of functional oligosaccharides added is 2% to 5% of the volume of the fermentation medium. Fermentation is carried out at 37 °C, pH 6.5 to 7.0, under anaerobic conditions for 48 to 72 hours. The supernatant is then collected by centrifugation. The supernatant is concentrated to a solid content of 20% to 30%, pre-frozen, freeze-dried, ground, pulverized, and sieved to obtain the functional small molecule metabolites.

[0032] A second aspect of this invention provides a method for preparing microcapsules based on functional oligosaccharides, probiotics, and their metabolites, the method comprising the following steps: S1: Mix probiotic freeze-dried powder, low-ester amidated pectin, and sodium alginate evenly, add water and knead into a soft mass, sieve to obtain wet granules; dry the wet granules in a fluidized bed to obtain the probiotic powder core; S2: Prepare a coating solution with a total solid content of 8%~10% by mixing yeast protein and functional oligosaccharides in a mass ratio; put the probiotic powder core obtained in S1 into a fluidized bed coating machine, spray the functional oligosaccharide-yeast protein combined coating solution onto the surface of the probiotic powder core to form a coating, and continue fluidized drying to obtain double-layer particles. S3: Dissolve the pH-sensitive enteric material, the lyophilized powder of the functional small molecule metabolite complex, and the plasticizer in water to prepare a coating solution with a total solid content of 15%~20%; put the bilayer particles obtained in S2 into a fluidized bed coating machine, spray the enteric coating solution of the functional small molecule metabolite complex onto the surface of the bilayer particles to form a coating, continue fluidized drying, and finally obtain the microcapsules.

[0033] Furthermore, in step S1, the particle size of the wet particles is 90~120 μm.

[0034] Furthermore, in step S1, the drying temperature is 35~38 ℃.

[0035] Furthermore, in step S2, the inlet air temperature of the fluidized bed coating machine is 38~40 ℃.

[0036] Furthermore, in step S2, the outlet air temperature of the fluidized bed coating machine is 30~35 ℃.

[0037] Furthermore, in step S2, the atomization pressure of the fluidized bed coating machine is 0.1~0.15 MPa.

[0038] Furthermore, in step S2, the spraying rate is 1~2 mL / min.

[0039] Furthermore, in step S2, the diameter of the bilayer particles is 120~140 μm.

[0040] Furthermore, in step S3, the inlet air temperature of the fluidized bed coating machine is 35~38 ℃.

[0041] Furthermore, in step S3, the outlet air temperature of the fluidized bed coating machine is 28~32 ℃.

[0042] Furthermore, in step S3, the atomization pressure of the fluidized bed coating machine is 0.1~0.12 MPa.

[0043] Furthermore, in step S3, the spraying rate is 0.5~1 mL / min.

[0044] A third aspect of this invention provides the application of microcapsules based on functional oligosaccharides, probiotics, and their metabolites in the preparation of pharmaceuticals or functional foods.

[0045] Furthermore, the functional food is in the form of powder or solid beverage.

[0046] Furthermore, the functional foods are used to regulate gut microbiota, improve mood, or serve as dietary supplements.

[0047] Compared with the prior art, the present invention has the following technical advantages: (1) This invention innovatively places probiotic small molecule metabolites in the outermost functional small molecule metabolite complex enteric coating and the probiotic composition in the innermost probiotic powder core. It utilizes two different release mechanisms—outer layer pH triggering and core pectinase triggering—to achieve the sequential delivery of metabolites preferentially released in the upper and middle part of the small intestine and probiotics delayed in the colon. The functional small molecule metabolites first relieve acute stress, and after the probiotics colonize, they continuously produce endogenous metabolites to maintain long-term regulation. The two work together to solve the core pain points of existing probiotic products, such as slow onset and short duration of effect. This provides a new option for people with intestinal flora imbalance, emotional imbalance, and psychological stress, which is fast-acting, highly efficient, and has a synergistic effect of sugar and bacteria.

[0048] (2) The metabolites of this invention are derived from the fermentation products of functional oligosaccharides by probiotics, forming a specific synergistic effect with probiotics. The added functional small molecule metabolite complexes such as butyric acid, 5-hydroxytryptamine, phenyllactic acid, indoleacetic acid, and indolelacic acid not only directly exert their gut-brain axis regulatory effects through HDAC inhibition, GPR activation, or microglia regulation, but also act as signaling molecules to promote the intestinal colonization of probiotics. At the same time, the functional small molecule metabolites are pre-added to the microcapsules, so they can take effect without waiting for probiotic colonization, and have a rapid intervention capability for acute stress. In vitro simulation experiments show that the microcapsules of this invention can detect a significant increase in short-chain fatty acids within 4 hours, which is about 6 hours shorter than that of traditional lactic acid bacteria or bifidobacteria (which require more than 10 hours); in animal experiments, a significant decrease in serum corticosterone levels was observed 2 hours after administration, while there was no change in the traditional probiotic group.

[0049] (3) This invention achieves precise pairing of functional oligosaccharides based on the metabolic characteristics of bacterial strains. These functional oligosaccharides are specific substrates for probiotics. Specifically, Anaerobutyricum soehngenii Butyric acid is produced using neo-agnaphalose. Coprococcus companion Butyric acid is synthesized from acetic acid. Lachnoclostridium phocaeense It can inhibit the proliferation of pathogens through mechanisms such as occupying intestinal adhesion sites, secreting antibacterial substances, and producing acid to lower intestinal pH. Anaerobutyricum soehngenii and Coprococcus comesus The colonization of these bacteria provides a stable microecological environment, further enhancing the colonization stability of the complex microbiota in the gut. The three-bacterial relay metabolism formed in this invention increases total butyrate production by 1.2 to 1.5 times compared to single oligosaccharides and by 3.8 times compared to conventional fructooligosaccharide blends. This precise matching of probiotics and functional oligosaccharides achieves true synergistic effects between the sugar and bacteria.

[0050] (4) The microcapsules of the present invention adopt a three-layer composite structure, wherein the probiotic powder core uses low-ester amidated pectin and sodium alginate, the functional oligosaccharide-yeast protein combination coating layer utilizes the electrostatic self-assembly of functional oligosaccharides and yeast proteins, and the functional small molecule metabolite complex enteric coating layer utilizes pH-sensitive material (Eudragit), replacing the traditional single-layer encapsulation. Through the formation of a gel protective layer by sodium alginate in gastric juice, the formation of a dense composite aggregate layer by the self-assembly of functional oligosaccharide-yeast protein combination coating at pH 4.0~4.5, and the preservation of the functional small molecule metabolite complex enteric coating at gastric acid (pH < 5.8), a triple barrier is formed, which enables the survival rate of probiotics ≥ 89% after 2 hours of treatment in simulated gastric juice (pH 1.2), which is about 17 times higher than that of unencapsulated free probiotics (survival rate < 5%), and about 70% higher than that of traditional sodium alginate single-layer encapsulation.

[0051] (5) This invention uses yeast protein with neuroregulatory activity as the main wall material for the functional oligosaccharide-yeast protein composite coating, replacing traditional inert wall materials such as sodium alginate and gelatin. After the Saccharomyces cerevisiae protein is degraded and released in the intestine, the bioactive peptides it releases can be absorbed into the bloodstream through the intestine, regulate neuroendocrine function, reduce stress-induced corticosterone secretion, and achieve synergistic effects of the wall material and core material of the microcapsule in regulating enterobrain function. Attached Figure Description

[0052] Figure 1 This is a schematic diagram of the structure of the microcapsule of the present invention. Detailed Implementation

[0053] The present invention will now be described in detail with reference to the accompanying drawings and specific embodiments. These embodiments are based on the technical solution of the present invention and provide detailed implementation methods and specific operating procedures. However, the scope of protection of the present invention is not limited to the following embodiments.

[0054] The purpose of this invention is to overcome the shortcomings of existing technologies and provide a microcapsule based on functional oligosaccharides, probiotics, and their metabolites, along with its preparation method and applications. The microcapsules of this invention can serve as a time-sequential delivery system for functional oligosaccharides, probiotics, and their metabolites to improve mood. Through time-sequential delivery design, pre-positioning of probiotic metabolites, and targeted feeding of probiotics with oligosaccharides, it solves the technical problems of low probiotic survival rate, slow onset of action, and poor stability of sugar-bacteria synergistic effects in traditional products, making it more suitable for daily mood regulation in sub-healthy individuals.

[0055] like Figure 1 As shown, the 3D microcapsule of the present invention comprises two functional parts: The first functional component mainly consists of metabolites, which are preferentially released in the upper and mid-intestinal tract (duodenum and jejunum) as small molecule metabolites. These small molecule metabolites are produced by probiotics during fermentation using functional oligosaccharides as substrates. The functional oligosaccharides involved can be specifically utilized and metabolized by probiotics. The second functional component mainly consists of probiotics and functional oligosaccharides, which are released in the colon. The probiotics utilize the functional oligosaccharides and colonize in the colon, continuously producing endogenous metabolites to achieve long-term maintenance.

[0056] Specifically, the 3D microcapsule structure of the present invention comprises, from the inside out, a probiotic powder core, a functional oligosaccharide-yeast protein combination coating, and a functional small molecule metabolite complex enteric coating.

[0057] In some specific embodiments, the probiotic powder core is prepared from probiotic freeze-dried powder, low-ester amidated pectin, and sodium alginate in a mass ratio of (15~25):(10~16):(1~2), accounting for 45%~55% of the total mass of the microcapsules. The low-ester amidated pectin has a degree of esterification (DE) < 50% and a degree of amidation (DA) of 20%~35%. This material is essentially insoluble or only slightly swollen in gastric acid (pH 1.2) and small intestinal fluid (pH 6.8). Upon reaching the colon, it is specifically degraded by pectinase secreted by the colonic flora, thereby precisely releasing the probiotics. Sodium alginate acts as a binder to aid granulation and simultaneously forms a gel layer in gastric fluid, providing additional acid protection.

[0058] Among them, probiotic freeze-dried powder is selected from Anaerobutyricum soehngenii DSM 17630 (deposited at the German Collection of Microbial Cultures, DSMZ) Coprococcus comesus ATCC 27758 (deposited at the American Center for Type Culture Collection, ATCC) Lachnoclostridium phocaeense One or more strains of DSM 103528 (deposited at the German Collection of Microbial Cultures, DSMZ) are used. All strains mentioned above were purchased from publicly available commercial sources, and the total bacterial count in the probiotic freeze-dried powder is not less than 1.0 × 10⁻⁶. 8 CFU / g.

[0059] In some specific embodiments, the functional oligosaccharide-yeast protein combination coating is prepared by mixing yeast protein and functional oligosaccharides at a mass ratio of (15~25):(10~15), accounting for 30%~35% of the total mass of the microcapsules, with a thickness of 10~15 μm. The yeast protein is *Saccharomyces cerevisiae* (Saccharomyces cerevisiae). Saccharomyces cerevisiae Yeast proteins, obtained through controlled enzymatic hydrolysis using yeast as a raw material, have peptides with molecular weights mainly ranging from 5000 to 30000 Da. Rich in glutamate, GABA precursors, and bioactive peptides, they possess neuroregulatory activity, interacting with receptors on the surface of intestinal epithelial cells or intestinal endocrine cells to regulate the activity of the hypothalamus-pituitary-adrenal (HPA) axis, reduce corticosterone secretion, and exert a soothing and anti-anxiety effect. Simultaneously, yeast proteins carry a positive charge near their isoelectric point (pH 4.0–4.5), allowing them to undergo electrostatic self-assembly with negatively charged functional oligosaccharides, forming a dense, complex aggregate layer.

[0060] In some specific embodiments, the functional oligosaccharide is selected from one or more of neo-agnatase, 2'-FL, xylotriose, chitobiose, and maltotetraose, serving as a targeted substrate for probiotics. The coating layer gradually dissolves after metabolite release, releasing oligosaccharides and yeast proteins. The yeast proteins can be absorbed by the intestines to exert a mood-soothing effect, while the oligosaccharides diffuse downstream into the colon, providing an immediate nutritional source for subsequently released probiotics.

[0061] In some specific embodiments, the functional small molecule metabolite complex enteric coating is prepared from a metabolite-resistant dextrin complex, a pH-sensitive enteric material, and a plasticizer in a mass ratio of (10-20):(10-16):(1-4), accounting for 15%-25% of the total mass of the microcapsules, with a thickness of 8-14 μm. The resistant dextrin is selected from one or more of high-branched corn starch-based water-soluble resistant dextrin with a DE value of 3-6, esterified resistant dextrin, and cassava-based resistant dextrin with a DE value of 6-10. The metabolite is pre-formed with the resistant dextrin to address oxidation, volatilization, and unpleasant odor issues during storage and processing, protecting the stability of the metabolite during processing. The pH-sensitive enteric material is Eudragit L30D-55 aqueous dispersion (30% solids content). This functional small molecule metabolite complex enteric coating dissolves in the upper small intestine, thereby achieving rapid release of the metabolite from the duodenum to the jejunum. The plasticizer is triethyl citrate, which accounts for 5% to 15% of the total mass of the functional small molecule metabolite complex enteric coating. It is used to increase the flexibility of the coating film. The increase in weight of the functional small molecule metabolite complex enteric coating is 15% to 25% of the mass of the bilayer particles.

[0062] In some specific embodiments, the functional small molecule metabolites are fermentation products obtained by co-fermentation of the above-mentioned probiotics and functional oligosaccharides, which are then freeze-dried.

[0063] In some specific embodiments, the probiotics are Anaerobutyricum soehngenii , Coprococcus comesus and Lachnoclostridium phocaeense The combination of the three components has a mass ratio of (15~25):(10~15):(5~10). Among them, Anaerobutyricum soehngenii During metabolism, acetic acid is consumed to synthesize butyric acid, which has stronger activity and a more significant gut-brain axis regulatory effect; Coprococcus comesus On the one hand, it can efficiently utilize acetic acid to synthesize butyric acid, and on the other hand, it can generate DOPAC through a unique DOPAC synthesis pathway, which directly acts on the dopamine metabolism pathway. Lachnoclostridium phocaeense It participates in the synthesis of GABA. After the three bacteria are combined, the total butyric acid production is increased by 1.2 to 1.5 times compared with the sum of the production of the single bacteria, the DOPAC production is increased (≥0.5 mg / g), and the GABA production is increased by 1.2 to 1.5 times compared with the sum of the production of the single bacteria, achieving multi-target synergy and significantly improving the mood improvement effect.

[0064] In some specific embodiments, the probiotics are Anaerobutyricum soehngenii , Coprococcus comesus and Lachnoclostridium phocaeenseThe combination of functional oligosaccharides consists of neo-agnaphthosaccharide, 2'-FL, xylitol, chitobiose, and maltotetraose, in a mass ratio of (15~35): (8~20): (5~20): (3~5): (3~15). Neo-agnaphthosaccharide can be... Anaerobutyricum soehngenii It decomposes into neoadenosyltetraose and neoadenosylbiose, entering the butyrate synthesis pathway; xylotriose and 2'-FL can be... Coprococcus comesus and Lachnoclostridium phocaeense Hydrolysis allows it to enter butyrate synthesis via the pentose phosphate pathway; chitobiose and maltotetraose can serve as supplementary carbon sources and are metabolized and utilized under the synergistic effect of the microbial community, continuously supplying precursor substances for the butyrate production pathway.

[0065] In some specific embodiments, the probiotics are Anaerobutyricum soehngenii, Coprococcus comesus and Lachnoclostridium phocaeense When combined, the lyophilized powder of the functional small molecule metabolite complex contains one or more of butyric acid, serotonin, phenyllactic acid, indoleacetic acid, and indolelacic acid. Specifically, the butyric acid content is 5%~7% (mass fraction), the serotonin content is 0.01%~0.02% (mass fraction), the phenyllactic acid content is 0.5%~1.0% (mass fraction), the indoleacetic acid content is 0.1%~0.3% (mass fraction), and the indolelacic acid content is 0.05%~0.15% (mass fraction). It is added directly to microcapsules and exerts its effect immediately upon reaching the colon, without waiting for probiotics to colonize and produce acid in the intestines, resulting in faster efficacy.

[0066] This invention also provides a method for preparing microcapsule products based on functional oligosaccharides, probiotics, and their metabolites, specifically including the following steps: S1. Prepare lyophilized probiotic powder and lyophilized functional small molecule metabolite complex powder, and prepare the probiotic powder core, and dry them.

[0067] S2. Prepare a mixed solution of yeast protein and oligosaccharides, and coat it with a fluidized bed to form a uniform layer of functional oligosaccharide-yeast protein combination coating on the core surface of the probiotic powder. Dry it to obtain double-layer particles.

[0068] S3. Prepare an enteric coating solution of functional small molecule metabolite complex, and coat it with a fluidized bed to form an enteric coating of functional small molecule metabolite complex on the surface of the double-layer particles. Dry it to obtain the time-delivery system product of the functional oligosaccharide-probiotic and its metabolites that improves mood.

[0069] In some specific embodiments, in step S1, the method for preparing the probiotic freeze-dried powder is as follows: The target strain was inoculated onto solid culture plates and cultured anaerobically at 37 °C for 48–72 hours. Single colonies were then picked for purification. The purified single colonies were inoculated into liquid culture medium and cultured anaerobically at 37 °C for 24–36 hours to obtain a seed culture. The seed culture was then inoculated into a fermenter at an inoculation rate of 5%–10% and fermented anaerobically at 37 °C, pH 6.5–7.0 for 24–48 hours until the viable probiotic count reached 1.0 × 10⁻⁶. 8 ~1.0×10 9 CFU / mL; centrifuge the fermentation broth at 8000-10000 rpm for 15-20 minutes at 4 ℃ and collect the bacterial sludge. Prepare a compound freeze-drying protectant, by mass percentage: 10%-20% skim milk powder, 5%-10% trehalose, 1% monosodium glutamate, 0.5% cysteine ​​hydrochloride, with the remainder being sterile water. Mix the bacterial sludge with the pre-cooled compound freeze-drying protectant at a mass ratio of 1:2-1:3. Pre-freeze the mixture at -40 ℃ for 4-6 hours, then freeze-dry it under vacuum <10 Pa and cold trap temperature <-60 ℃ for 24-36 hours; grind the dried material at ≤ 4 ℃ and pass it through a 100-mesh sieve to obtain probiotic freeze-dried powder with a probiotic viable count of not less than 1.0×10⁻⁶. 8 CFU / g.

[0070] In some specific embodiments, in step S1, the preparation method of the probiotic powder core is as follows: Mix probiotic freeze-dried powder, low-ester amidated pectin, and sodium alginate evenly according to the mass ratio; add 5%~8% sterile water (pre-cooled to 4℃) to the total mass of the dry powder, and quickly knead into a soft mass for no more than 1 minute. Pass the soft mass through a 120~150 mesh sieve to form wet granules with a diameter of 90~120 μm; place the wet granules in a fluidized bed at 35~38℃ and dry for 25~30 minutes until the moisture content is ≤ 5%, to obtain the probiotic powder core.

[0071] In some specific embodiments, the preparation method of the functional oligosaccharide-yeast protein combination coating in step S2 is as follows: Yeast protein and functional oligosaccharides were dissolved in sterile water at a mass ratio to prepare a coating solution with a total solids content of 8% to 10%. The prepared probiotic powder core was put into a fluidized bed coating machine, with the inlet air temperature set at 38 to 40 ℃, the outlet air temperature at 30 to 35 ℃, and the atomization pressure at 0.1 to 0.15 MPa. The coating solution was sprayed onto the surface of the probiotic powder core at a rate of 1 to 2 mL / min, and the coating weight gain was 60% to 75% of the core mass. After coating, fluidized drying was continued for 10 to 15 minutes until the moisture content was ≤ 4%, resulting in double-layer particles with a diameter of 120 to 140 μm.

[0072] In some specific embodiments, the method for preparing the enteric coating of the functional small molecule metabolite complex in step S3 is as follows: 10-16 parts (corresponding to 33-53 parts by mass) of pH-sensitive enteric material Eudragit L30D-55 aqueous dispersion, 10-20 parts of metabolite-resistant dextrin complex, and 1.0-2.5 parts of triethyl citrate were dissolved in deionized water and stirred until homogeneous to prepare a coating solution with a total solids content of 15%-20%. The prepared bilayer particles were fed into a fluidized bed coating machine with an inlet air temperature of 35-38 ℃, an outlet air temperature of 28-32 ℃, and an atomization pressure of 0.1-0.12 MPa. The functional small molecule metabolite complex enteric coating solution was sprayed onto the surface of the bilayer particles at a rate of 0.5-1 mL / min, resulting in a coating weight gain of 15%-25% of the particle mass. After coating, fluidized drying was continued for 15-20 minutes until the moisture content was ≤ 5%, yielding the final microcapsules with a diameter of 140-170 μm.

[0073] Each of the above embodiments can be implemented individually, or in any combination of two or more. The following detailed description of specific examples will further illustrate these embodiments.

[0074] Unless otherwise specified, the reagents, methods, instruments, and equipment used in this invention are conventional in the art. Unless otherwise specified, the reagents and materials used in the following examples are all commercially available.

[0075] In the following embodiments Anaerobutyricum soehngenii DSM 17630 is deposited at the German Collection of Microbial Cultures, DSMZ.

[0076] In the following embodiments Coprococcus comesus ATCC 27758, deposited at the American Center for Type Culture Collection (ATCC).

[0077] In the following embodiments Lachnoclostridium phocaeense DSM 103528 is deposited at the German Collection of Microbial Cultures, DSMZ.

[0078] In the following examples, the yeast protein is brewer's yeast (Saccharomyces cerevisiae). Saccharomyces cerevisiae) Yeast protein hydrolysate was prepared by enzymatic hydrolysis using yeast as raw material. The yeast strain is... Saccharomyces cerevisiaeCICC 1001 (purchased from the China Industrial Microbial Culture Collection Center). The specific preparation method is as follows: Saccharomyces cerevisiae was inoculated into YPD medium and cultured at 30 ℃ for 18–24 h. The cells were collected by centrifugation and subjected to cell wall disruption to obtain yeast protein extract. Food-grade complex protease (including alkaline and neutral protease) was added, and the pH was adjusted to 7.0–8.0. Enzymatic hydrolysis was carried out at 45–55 ℃ for 4–8 h. After hydrolysis, the enzyme was inactivated, and insoluble matter was removed by centrifugation. The resulting yeast protein hydrolysate was freeze-dried. Gel permeation chromatography analysis showed that the obtained yeast protein hydrolysate mainly consisted of peptides of different molecular weights, with the molecular weights of these peptides primarily distributed in the range of 5000–30000 Da.

[0079] In the following examples, the resistant dextrin is specifically corn starch-based water-soluble resistant dextrin, purchased from Shandong Bailong Chuangyuan Biotechnology Co., Ltd.

[0080] Example 1: This embodiment provides a microcapsule product based on functional oligosaccharides, probiotics, and their metabolites, comprising, from the inside out, a probiotic powder core, a functional oligosaccharide-yeast protein composite coating, and an enteric coating of a functional small molecule metabolite complex. The specific preparation method is as follows: S1. In the anaerobic workstation (85% N2, 10% H2, 5% CO2, 37 ℃), Anaerobic butyric acid soehngenii The lyophilized powder was dissolved in Medium 330 medium (pre-reduced for 24 hours) with 0.05% L-cysteine ​​hydrochloride and 30% rumen fluid added. Coprococcus comesus The lyophilized powder was dissolved in a modified YCFA medium (containing a mixture of volatile fatty acids) that had been pre-reduced for 24 hours. Lachnoclostridium phocaeense The lyophilized powder was dissolved in a modified PYG medium that had been pre-reduced for 24 hours.

[0081] S2, anaerobic culture at 37 ℃ for 48 hours, streak well-grown bacterial culture onto solid plates, pick single colonies and inoculate onto fresh liquid culture medium, culture to the late logarithmic growth phase, as the primary seed culture. Take 1 mL of the primary seed culture and mix with an equal volume of 30% sterile glycerol, store at -80 ℃ for later use.

[0082] S3, Take the sample stored at -80℃ Anaerobutyricum soehngenii One glycerol tube was rapidly thawed and inoculated into fresh pre-reduced Medium 330 medium at a 2% inoculum. It was then anaerobically cultured at 37 °C for 16 hours until the mid-logarithmic growth phase, serving as a secondary seed culture.

[0083] S4. Take the sample stored at -80℃. Coprococcus comesusOne glycerol tube was rapidly thawed and inoculated into fresh pre-reduced modified YCFA medium at a 2% inoculum. The medium was then anaerobically cultured at 37 °C for 16 hours until the mid-logarithmic growth phase, which served as the secondary seed culture.

[0084] S5. Take the sample stored at -80℃. Lachnoclostridium phocaeense One glycerol tube was rapidly thawed and inoculated into fresh pre-reduced modified PYG medium at a 2% inoculum. The medium was then anaerobic at 37 °C for 16 hours until the mid-logarithmic growth phase, which served as the secondary seed culture.

[0085] S6. Inoculate the three secondary seed cultures into their respective fermenters at an inoculation rate of 5% each: Anaerobic butyric acid soehngenii Using Medium 330 medium, Coprococcus comesus Use modified YCFA medium. Lachnoclostridium phocaeense Modified PYG medium was used. Fermentation was carried out at 37 ℃, pH 6.5-7.0, under anaerobic conditions for 36 hours until the viable count of probiotics reached 5 × 10⁻⁶. 8 CFU / mL, 4×10 8 CFU / mL and 3×10 8 CFU / mL.

[0086] S7. Centrifuge the fermentation broth at 9000 r / min for 18 minutes at 4 ℃, and collect the samples separately. Anaerobic butyric acid soehngenii 140 g of wet mycelium mud Coprococcus comesus 120 g of wet mycelium mud Lachnoclostridium Phocaean 100 g of wet fungal mud.

[0087] S8. Preparation of compound freeze-drying protectant: Weigh 75 g of skim milk powder, 40 g of trehalose, 5 g of sodium glutamate, and 2.5 g of cysteine ​​hydrochloride, add sterile water to a final volume of 500 mL, and stir until completely dissolved.

[0088] S9. Mix the bacterial sludge and pre-cooled protective agent at a mass ratio of 1:2.5, pre-freeze at -40 ℃ for 5 hours, and freeze-dry for 30 hours under vacuum conditions < 10 Pa and cold trap temperature < -60 ℃.

[0089] S10. The dried material is ground and pulverized at 4℃ and passed through a 100-mesh sieve to obtain... Anaerobutyricum soehngenii Freeze-dried powder (live bacteria count 1.2 × 10⁻⁶) 8 CFU / g), Coprococcus comesus Freeze-dried powder (live bacteria count 1.1 × 10⁻⁶) 8 CFU / g) and Lachnoclostridium phocaeense Freeze-dried powder (8×10⁶ live bacteria count) 7 CFU / g).

[0090] S11, Take Anaerobutyricum soehngenii Secondary seed liquid, Coprococcus comesus Secondary seed liquid and Lachnoclostridium phocaeense Secondary seed culture was mixed at a 1:1 ratio with viable cell counts, and 5% of the total inoculum was inoculated into the fermentation medium. The fermentation medium was a modified YCFA basal medium supplemented with 1.5% neo-agaroctaose, 0.8% 2'-FL, 0.5% xylotriose, 0.3% chitobiose, and 0.3% maltotetraose. Fermentation was carried out at 37 ℃, pH 6.8, under anaerobic conditions for 60 hours.

[0091] S12. Centrifuge the fermentation broth at 11000 r / min for 25 minutes at 4 ℃ and collect the supernatant.

[0092] S13. The supernatant is concentrated to 1 / 8 of its original volume under low temperature vacuum at 4 ℃, with a solid content of 25%.

[0093] S14. The concentrate is pre-frozen at -40 ℃ for 5 hours and freeze-dried at a vacuum of < 10 Pa and a cold trap temperature of < -60 ℃ for 30 hours.

[0094] S15. The dried material was ground and pulverized at 4 ℃ and passed through a 100-mesh sieve to obtain a lyophilized powder of functional small molecule metabolites. Testing revealed that the butyric acid content was 62 mg / g, the 5-hydroxytryptamine content was 0.15 mg / g, the phenyllactic acid content was 8.5 mg / g, the indoleacetic acid content was 2.3 mg / g, and the indolelactic acid content was 1.2 mg / g.

[0095] S16. The functional small molecule metabolite freeze-dried powder and highly branched corn starch-based water-soluble resistant dextrin are mixed at a mass ratio of 1:3 to prepare a metabolite-resistant dextrin complex.

[0096] S17, Take Anaerobutyricum soehngenii 12 g of freeze-dried powder Coprococcus comesus 8g of freeze-dried powder Lachnoclostridium phocaeense Mix 5 g of freeze-dried powder, 10 g of low-ester amidated pectin, and 1 g of sodium alginate dry for 10 minutes.

[0097] S18. Add 3.7 g of sterile water at 4 ℃ and knead quickly for 45 seconds until a soft mass is formed. Granulate the soft mass through a 130-mesh sieve to obtain wet granules.

[0098] S19. Wet granules are placed in a fluidized bed with an inlet air temperature of 38 ℃ and dried for 25 minutes until the moisture content is 4.2%.

[0099] S20. Sieve to collect particles of 90-120 μm to obtain the probiotic powder core. Testing showed a live bacteria count of 3.0 × 10⁻⁶. 8 CFU / g.

[0100] S21. Take 12 g of yeast protein, 14 g of neo-agaroctaose, 5 g of 2'-FL, 3 g of xylotriose, 2 g of chitobiose, and 2 g of maltotetraose, dissolve them in 340 mL of sterile water to prepare a coating solution with a total solids content of 9%.

[0101] S22. The probiotic powder core is fed into a fluidized bed coating machine, with the inlet air temperature set at 38 ℃, the outlet air temperature at 32 ℃, and the atomization pressure at 0.12 MPa. The liquid is sprayed at a rate of 1.5 mL / min, resulting in a coating weight gain of 65%.

[0102] S23. After coating, fluidize and dry at 38 °C for 12 minutes until the moisture content is 3.8%. This yields bilayer particles with a diameter of 125~138 μm.

[0103] S24. Take 50 g of Eudragit L30D-55 aqueous dispersion (30% solid content) (equivalent to 15 g of dry matter), 10 g of metabolite-resistant dextrin complex, and 1.5 g of triethyl citrate. Add deionized water to a total mass of 100 g, stir well, and prepare a coating solution with a total solid content of about 20%.

[0104] S25. The double-layer particles are fed into a fluidized bed coating machine, with the inlet air temperature set at 36 ℃, the outlet air temperature at 30 ℃, and the atomization pressure at 0.11 MPa. The liquid is sprayed at a rate of 0.8 mL / min, resulting in a coating weight gain of 18%.

[0105] S26. After coating, fluidize and dry at 36 ℃ for 18 minutes until the moisture content is ≤ 5%. The final microcapsules are obtained with a diameter of 140~170 μm.

[0106] The specific formula is as follows: Probiotic Powder Core Anaerobutyricum soehngenii 12g of freeze-dried powder Coprococcus comesus 8g of freeze-dried powder Lachnoclostridium phocaeense 5 g of freeze-dried powder, 10 g of low-ester amidated pectin, 1 g of sodium alginate, and 3.7 mL of sterile water at 4 ℃.

[0107] Functional oligosaccharide-yeast protein combination coating: 12 g yeast protein, 14 g neo-agnatic octaose, 5 g 2'-FL, 3 g xylotriose, 2 g chitobiose, 2 g maltotetraose, 340 mL sterile water.

[0108] Enteric coating of functional small molecule metabolite complex: 50 g of Eudragit L30D-55 aqueous dispersion (15 g dry matter), 10 g of metabolite-resistant dextrin complex, 1.5 g of triethyl citrate, and 38.5 mL of deionized water.

[0109] Example 2: This embodiment provides a microcapsule product based on functional oligosaccharides, probiotics, and their metabolites, comprising, from the inside out, a probiotic powder core, a functional oligosaccharide-yeast protein composite coating, and an enteric coating of a functional small molecule metabolite complex. The specific preparation method is as follows: S1. The preparation of probiotic freeze-dried powder and secondary seed liquid is the same as in Example 1.

[0110] S2, take Anaerobutyricum soehngenii Secondary seed liquid, Coprococcus comesus Secondary seed liquid and Lachnoclostridium phocaeense Secondary seed culture was mixed at a 1:1 ratio with viable cell counts, and 5% of the total inoculum was inoculated into the fermentation medium. The fermentation medium was a modified YCFA basal medium supplemented with 1.0% neo-agaroctaose, 0.5% 2'-FL, 0.3% xylotriose, 0.4% chitobiose, and 0.3% maltotetraose. Fermentation was carried out at 37 ℃, pH 6.8, under anaerobic conditions for 60 hours.

[0111] S3. Centrifuge the fermentation broth at 11000 r / min for 25 minutes at 4 ℃ and collect the supernatant.

[0112] S4. The supernatant was concentrated to 1 / 8 of its original volume under low temperature vacuum at 4 ℃, with a solid content of 25%.

[0113] S5. The concentrate is pre-frozen at -40 ℃ for 5 hours, and then freeze-dried at a vacuum of < 10 Pa and a cold trap temperature of < -60 ℃ for 30 hours.

[0114] S6. The dried material was ground and pulverized at 4 ℃ and passed through a 100-mesh sieve to obtain a lyophilized powder of functional small molecule metabolite complex. Testing revealed that it contained 60 mg / g of butyric acid, 0.18 mg / g of 5-hydroxytryptamine, 9.1 mg / g of phenyllactic acid, 2.5 mg / g of indoleacetic acid, and 1.4 mg / g of indolelactic acid.

[0115] S7. The lyophilized powder of functional small molecule metabolite complex is mixed with esterified modified resistant dextrin at a mass ratio of 1:3 to prepare metabolite-resistant dextrin complex.

[0116] S8. Take 9 g of Anaerobutyricum soehngenii lyophilized powder and 6 g of Coprococcus comes lyophilized powder. Lachnoclostridium phocaeense Mix 4 g of freeze-dried powder, 10 g of low-ester amidated pectin, and 1 g of sodium alginate dry for 10 minutes.

[0117] S9. Add 3.0 g of sterile water at 4 ℃, knead quickly for 45 seconds, granulate through a 130-mesh sieve to obtain wet granules.

[0118] S10 wet granules are placed in a fluidized bed, with an inlet air temperature of 38 ℃, and dried for 25 minutes until the moisture content is 4.1%.

[0119] S11. Sieve and collect particles of 90-120 μm to obtain the probiotic powder core. Testing showed a live bacteria count of 2.8 × 10⁻⁶. 8 CFU / g.

[0120] S12. Take 12 g of yeast protein, 12 g of neo-agaroctaose, 4 g of 2'-FL, 3 g of xylotriose, 3 g of chitobiose, and 3 g of maltotetraose, dissolve them in 320 mL of sterile water to prepare a coating solution with a total solids content of 9%.

[0121] S13. The probiotic powder core is fed into a fluidized bed coating machine, with the inlet air temperature set at 38 ℃, the outlet air temperature at 32 ℃, and the atomization pressure at 0.12 MPa. The liquid is sprayed at a rate of 1.5 mL / min, resulting in a coating weight gain of 65%.

[0122] S14. After coating, fluidize and dry at 38 °C for 12 minutes until the moisture content is 3.8%. This yields bilayer particles with a diameter of 125~138 μm.

[0123] S15. Take 50 g of Eudragit L30D-55 aqueous dispersion (30% solid content) (equivalent to 15 g of dry matter), 10 g of metabolite-resistant dextrin complex, and 1.5 g of triethyl citrate. Add deionized water to a total mass of 100 g, stir well, and prepare a coating solution with a total solid content of about 20%.

[0124] S16. The double-layer particles are fed into a fluidized bed coating machine, with the inlet air temperature set at 36 ℃, the outlet air temperature at 30 ℃, and the atomization pressure at 0.11 MPa. The liquid is sprayed at a rate of 0.8 mL / min, resulting in a coating weight gain of 18%.

[0125] S17. After coating, fluidize and dry at 36 ℃ for 18 minutes until the moisture content is ≤ 5%. The final microcapsules are obtained with a diameter of 140~170 μm.

[0126] The specific formula is as follows: Probiotic powder core: Anaerobutyricum soehngenii 9 g of freeze-dried powder Coprococcus comesus 6 g of freeze-dried powder Lachnoclostridium phocaeense 4 g of freeze-dried powder, 10 g of low-ester amidated pectin, 1 g of sodium alginate, and 3 mL of sterile water at 4 ℃.

[0127] Functional oligosaccharide-yeast protein combination coating: 12g yeast protein, 12g neo-agnatic octaose, 4g 2'-FL, 3g xylotriose, 3g chitobiose, 3g maltotetraose, 320mL sterile water.

[0128] Functional small molecule metabolite complex enteric coating: Eudragit L30D-55 aqueous dispersion 50g (15 parts dry matter), metabolite-resistant dextrin complex 10g, triethyl citrate 1.5g, deionized water 38.5mL.

[0129] Example 3: This embodiment provides a microcapsule product based on functional oligosaccharides, probiotics, and their metabolites, comprising, from the inside out, a probiotic powder core, a functional oligosaccharide-yeast protein composite coating, and an enteric coating of a functional small molecule metabolite complex. The specific preparation method is as follows: S1. Preparation of probiotic freeze-dried powder is the same as in Example 1.

[0130] S2. Preparation of the lyophilized powder of the functional small molecule metabolite complex was the same as in Example 1. The results showed that the butyric acid content was 58 mg / g, the 5-hydroxytryptamine content was 0.14 mg / g, the phenyllactic acid content was 8.2 mg / g, the indoleacetic acid content was 2.0 mg / g, and the indolelactic acid content was 1.0 mg / g.

[0131] S3. The lyophilized powder of the functional small molecule metabolite complex is mixed with cassava-based resistant dextrin at a mass ratio of 1:3 to prepare the metabolite-resistant dextrin complex.

[0132] S4, Take Anaerobutyricum soehngenii 15 g of freeze-dried powder Coprococcus comesus 10g of freeze-dried powder Lachnoclostridium phocaeense Mix 5 g of freeze-dried powder, 14 g of low-ester amidated pectin, and 1.2 g of sodium alginate dry for 10 minutes.

[0133] S5. Add 4.2 g of sterile water at 4 ℃ and knead quickly for 50 seconds.

[0134] S6. Granulate through a 120-mesh sieve. Place the wet granules in a fluidized bed, with an inlet air temperature of 38 ℃, and dry for 25 minutes until the moisture content is ≤5%.

[0135] S7. Collect particles of 90~120 μm through sieving to obtain the probiotic powder core. The number of live bacteria was tested and found to be 3.2×108 CFU / g.

[0136] S8. Dissolve 10 g of yeast protein, 11 g of neo-agaroctaose, 5 g of 2'-FL, 2 g of xylotriose, 4 g of chitobiose, and 3 g of maltotetraose in 320 mL of sterile water to prepare a coating solution with a total solids content of 10%.

[0137] S9, the fluidized bed parameters are the same as in Example 1, the coating increases the weight by 70%, and after drying, double-layer particles with a diameter of 130~145 μm are obtained.

[0138] S10. Take 45 g of Eudragit L30D-55 aqueous dispersion (30% solid content) (equivalent to 13.5 g of dry matter), 9 g of metabolite-resistant dextrin complex, and 1.4 g of triethyl citrate. Add deionized water to a total mass of 90 g, stir well, and prepare a coating solution with a total solid content of about 20%.

[0139] S11. The double-layer particles are fed into a fluidized bed coating machine. The fluidized bed parameters are the same as in Example 1. The coating weight gain is 22%.

[0140] S12. After coating, fluidize and dry at 36 ℃ for 18 minutes until the moisture content is ≤ 5%, to obtain the final microcapsules with a diameter of 150~180 μm.

[0141] The specific formula is as follows: Probiotic powder core: Anaerobutyricum soehngenii 15 g of freeze-dried powder Coprococcus comesus 10 g of freeze-dried powder Lachnoclostridium phocaeense 5 g of freeze-dried powder, 14 g of low-ester amidated pectin, 1.2 g of sodium alginate, and 4.2 mL of sterile water at 4 ℃.

[0142] Functional oligosaccharide-yeast protein combination coating: 10 g yeast protein, 11 g neo-agnatic octaose, 5 g 2'-FL, 2 g xylotriose, 4 g chitobiose, 3 g maltotetraose, 320 mL sterile water.

[0143] Functional small molecule metabolite complex enteric coating: Eudragit L30D-55 aqueous dispersion 45 g (dry matter 13.5 g), metabolite-resistant dextrin complex 9 g, triethyl citrate 1.4 g, deionized water 34.6 mL.

[0144] Comparative Example 1: This comparative example provides a microcapsule in which probiotics, metabolites, functional oligosaccharides, and wall materials are all mixed and then encapsulated in a single layer, to demonstrate the significant improvement in the survival rate of probiotics by the three-layer structure of the present invention.

[0145] The difference from Examples 1-3 is that the microcapsules in this comparative example are single-layer calcium alginate gel beads, and the specific formula is: probiotic freeze-dried powder ( Anaerobutyricum soehngenii , Coprococcus comesus , Lachnoclostridium phocaeense The compound (in the same mass ratio as in Example 1) consists of 20 parts, metabolite-resistant dextrin complex (in the same mass ratio as in Example 1) consists of 30 parts, functional oligosaccharide (a compound of neo-agnatic octaose, 2'-FL, xylotriose, chitobiose, and maltotetraose, in the same mass ratio as in Example 1) consists of 26 parts, and sodium alginate consists of 10 parts.

[0146] The preparation process is as follows: S1, Probiotic freeze-dried powder is the same as in Example 1.

[0147] S2, The preparation of the lyophilized powder of the functional small molecule metabolite complex is the same as in Example 1.

[0148] S3. Mix the above-mentioned probiotic freeze-dried powder, functional small molecule metabolite complex freeze-dried powder, functional oligosaccharide, and sodium alginate evenly; add sterile water accounting for 8% of the total mass of the dry powder, and quickly knead into a soft material; pass the soft material through a 120-mesh sieve to make wet granules with a diameter of 100 μm.

[0149] S4. Drop the wet particles into a 2% calcium chloride solution and solidify for 30 minutes to form calcium alginate gel microcapsules. After washing with sterile water, dry in a fluidized bed at 38 ℃ for 20 minutes until the moisture content is ≤5% to obtain the final microcapsules.

[0150] The difference between this comparative example and Example 1 is that only a single layer of calcium alginate is used for encapsulation, without setting an independent functional oligosaccharide-yeast protein combination coating layer and a pH-sensitive functional small molecule metabolite complex enteric coating layer; probiotics, metabolites, and oligosaccharides are all mixed in the same core, making sequential release impossible; the wall material is traditional inert sodium alginate, which does not possess the neuroregulatory activity of yeast protein.

[0151] The probiotic survival rate test after 2 hours of treatment with simulated gastric juice (pH 1.2) showed that the probiotic survival rate of the comparative microcapsules was 48.5±3.2%, which was significantly lower than 92.0±1.8% in Example 1, demonstrating the significant improvement effect of the three-layer structure of the present invention on the probiotic survival rate.

[0152] Comparative Example 2: This comparative example provides a microcapsule containing only probiotic freeze-dried powder and functional oligosaccharides, without the addition of metabolites, to demonstrate the effect of the outer metabolites on rapid onset of action.

[0153] The difference from Examples 1-3 is that the functional small molecule metabolite complex enteric coating does not contain metabolite-resistant dextrin complex, but only pH-sensitive enteric material. The formula of the functional small molecule metabolite complex enteric coating in this comparative example is: Eudragit L30D-55 aqueous dispersion (15 parts dry matter), 1.5 parts triethyl citrate, and 38.5 parts deionized water.

[0154] The preparation process is as follows: S1. The preparation of the probiotic powder core is the same as in Example 1.

[0155] S2, The spray coating of the functional oligosaccharide-yeast protein combination is the same as in Example 1.

[0156] S3. Preparation of enteric coating for functional small molecule metabolite complexes: Eudragit L30D-55 aqueous dispersion and triethyl citrate were dissolved in deionized water and stirred until homogeneous to prepare a coating solution free of metabolite complexes. The bilayer particles were fed into a fluidized bed coating machine and fluidized bed coating was performed according to the parameters described in the example. The pure enteric coating resulted in a weight gain of 15% of the bilayer particle mass. The final microcapsules were obtained by drying.

[0157] The difference between this comparative example and the embodiment is that no metabolites are added to the enteric coating of the functional small molecule metabolite complex. It relies solely on the production of active metabolites after probiotic colonization, which cannot achieve preferential release of metabolites in the small intestine and thus cannot take effect quickly.

[0158] In vitro simulated intestinal fermentation experiments showed that the comparative microcapsules showed a significant increase in short-chain fatty acids only after 10 hours, with the lag period being about 6 hours longer than that of Example 1 (3.8 hours).

[0159] Comparative Example 3: This comparative example provides a three-layer microcapsule without low-ester amidated pectin. The difference from Example 1 is that low-ester amidated pectin is not added to the probiotic powder core; instead, sodium alginate is used as the core matrix, to demonstrate the key role of the low-ester amidated pectin in colon-targeted release and long-term colonization.

[0160] Specifically, the core formula of the probiotic powder in this comparative example is as follows: Anaerobutyricum soehngenii 12 g of freeze-dried powder Coprococcus comesus 8 g of freeze-dried powder Lachnoclostridium phocaeense 5 g of freeze-dried powder, 10.9 g of sodium alginate, and the rest remain unchanged.

[0161] The preparation method for the core probiotic powder is the same as S17-S20 in Example 1. The preparation methods for the functional oligosaccharide-yeast protein combination coating and the functional small molecule metabolite complex enteric coating are the same as in Example 1.

[0162] The difference between this comparative example and Example 1 is that the core does not contain low-ester amidated pectin, and the gel is formed solely by calcium ion cross-linking of sodium alginate. Calcium alginate gel remains intact in gastric acid, but gradually swells and releases its contents in intestinal fluid, failing to achieve strictly colon-targeted release.

[0163] In vivo colonization experiments of humanized mice with gut bacteria showed that, in the comparative control group, after 14 days of drug administration, the colonic contents showed... Anaerobutyricum soehngeniiThe absolute abundance was 2.85 ± 0.35 log CFU / g, significantly lower than the 9.32 ± 0.41 log CFU / g in Example 1; simultaneously, the hippocampal 5-HT level (248.45 ± 19.12 ng / g) and GABA level (95.35 ± 10.45 nmol / g) were also significantly lower than in Example 1. This indicates that the lack of colonic enzyme-triggered release from low-ester amidated pectin means that the probiotics are released prematurely in the small intestine and cannot efficiently colonize the colon, resulting in a decreased long-term regulatory effect. This demonstrates the key role of the low-ester amidated pectin of this invention in colon-targeted release and long-term colonization.

[0164] The present invention evaluated the following functions of the microcapsules of functional oligosaccharides-probiotics and their metabolites prepared in Examples 1-3 and the microcapsules prepared in Comparative Examples 1-3: 1. In vitro simulated gastrointestinal tract time-sequential release test: The prepared microcapsule samples were subjected to in vitro simulated gastrointestinal time-sequential release tests. The simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were prepared according to the methods for preparing simulated digestive fluids in the United States Pharmacopeia (USP). The simulated colonic fluid (SCF) was constructed following the in vitro simulated gastrointestinal digestive model reported by Chen et al.

[0165] in: The simulated gastric fluid was prepared according to the Simulated Gastric Fluid TS method in USP. Specifically, 2.0 g of sodium chloride and 3.2 g of pepsin were weighed, dissolved in 7.0 mL of hydrochloric acid and an appropriate amount of purified water, and the volume was adjusted to 1000 mL. The pH of the system was adjusted to 1.2 to obtain the simulated gastric fluid. The pepsin was derived from porcine gastric mucosa, and its enzyme activity was 800–2500 U / mg protein.

[0166] The simulated intestinal fluid was prepared according to the Simulated Intestinal Fluid TS method in the USP. Specifically, a basal solution was prepared using a phosphate buffer system, the pH was adjusted to 6.8, and pancreatin was added to create a simulated small intestinal digestive environment.

[0167] The simulated colonic fluid was prepared according to the method reported by Chen et al. (Chen, JY, Chen, QM, Xie, CQ, Ahmad, W., Jiang, LH, & Zhao, LM (2020). Effects of simulated gastric and intestinal digestion on chitooligosaccharides in two in vitro models. International Journal of Food Science and Technology, 55(5), 1881-1890.). Specifically, fecal samples were collected from healthy donors, diluted and homogenized with sterile physiological saline, and then used as inoculum. The inoculum was inoculated into anaerobic culture medium, and a specific pectinase was added to adjust the pH of the system to 6.0. The system was then cultured under anaerobic conditions to establish a simulated colonic microecological environment.

[0168] The specific experimental steps are as follows: Simulated stomach stage (0~2 h): 1.0 g of each group of microcapsule samples were placed in simulated gastric juice (SGF, pH 1.2) containing pepsin and shaken at 37 ℃ for 2 hours.

[0169] Simulated small intestine stage (2-4 h): The system was transferred to simulated small intestinal fluid (SIF, pH 6.8) containing pancreatic enzymes and shaken at 37 °C for 2 hours.

[0170] Simulated colon stage (4-8 h): The system was transferred to simulated colon fluid (SCF, pH 6.0) containing healthy human fecal inoculum and specific pectinase, and anaerobically shaken for 4 hours.

[0171] Sampling was performed in stages, and the cumulative release rate of metabolites in the supernatant was determined by gas chromatography-mass spectrometry (GC-MS). The percentage of released probiotics relative to the total number of probiotics was determined by plate counting combined with flow cytometry.

[0172] The cumulative release rate of metabolites = (cumulative mass of metabolites released in the digestive fluid at each time point / theoretical total mass of pre-contained metabolites in the microcapsule) × 100%.

[0173] Probiotic cumulative release rate = (total cumulative number of probiotics released in digestive fluid at each time point / total number of probiotics initially encapsulated in microcapsules) × 100%.

[0174] The test results are shown in Table 1.

[0175] Table 1. Time-sequential release rate measurements during simulated gastrointestinal digestion in vitro. As shown in Table 1, the time-series release test results of the simulated gastrointestinal tract in in vitro experiments reveal that the metabolite release rate and probiotic release rate of Examples 1-3 in the gastric stage were significantly lower than those of Comparative Examples 1 and 2, indicating that the three-layer structure of the present invention can effectively resist gastric acid. In the small intestine stage, the metabolite release rate of Examples 1-3 was significantly higher than that of Comparative Example 1 (without outer layer metabolites), while the probiotic release rate was significantly lower than that of Comparative Example 1, but significantly higher than that of Comparative Example 3 (without inner layer pectin). Comparative Example 3 achieved a probiotic release rate of 78.45% in the small intestine stage, indicating that due to the lack of low-ester amidated pectin in the core, the sodium alginate matrix dissolved and released probiotics prematurely in the intestinal fluid, failing to achieve colon-targeted release. In contrast, the release rate of the Example group was less than 3% in the small intestine stage and more than 95% in the colon stage, demonstrating the key role of low-ester amidated pectin in the core of the present invention for colon-targeted release.

[0176] This demonstrates that the present invention, by placing metabolites in an outer pH-sensitive functional small molecule metabolite complex enteric coating and placing probiotics in a core low-esterified pectin, is significantly superior to the comparative examples, achieving a time-sequential delivery of metabolites preferentially released in the small intestine and probiotics delayed in the colon.

[0177] 2. Metabolite efficacy test of humanized gut bacteria in mice: Germ-free mice aged 6–8 weeks (GF mice) were selected and administered a combination of antibiotics (vancomycin (100 mg / kg BW), neomycin sulfate (200 mg / kg BW), metronidazole (200 mg / kg BW), and ampicillin (200 mg / kg BW)) via gavage for 14 consecutive days to eliminate the in situ intestinal flora. Fecal samples from 5 human donors exhibiting significant anxiety / depression symptoms were prepared into a 10% fecal suspension and transplanted into recipient mice via gavage for 3 consecutive days. One week after the flora reached equilibration, a 21-day chronic unpredictable stress (CUMS) model was established in the humanized mice.

[0178] After modeling, the mice were randomly divided into three groups: the example group, the control group (excluding the outer metabolite), and the model group (CK), with 10 mice in each group. The mice were administered 200 mg / kg by gavage daily for one day (only for the first administration). The model group was administered an equal volume of physiological saline by gavage.

[0179] Two hours after the first administration, mouse serum was collected, and the level of corticosterone (CORT) in the serum was measured by enzyme-linked immunosorbent assay (ELISA).

[0180] The test results are shown in Table 2.

[0181] Table 2. Serum CORT values ​​in humanized mice 2 hours after the first administration of Enterobacteriaceae. As shown in Table 2, the serum CORT levels in humanized mice 2 hours after the first administration of the enterobiotic were significantly lower in Examples 1-3 than in Comparative Examples 1 and 2, while the corticosterone level in Comparative Example 3 was slightly higher than that in the Example groups but still significantly lower than that in Comparative Example 1. This indicates that the metabolites in the outermost layer of this invention are rapidly released and absorbed into the bloodstream in the small intestine, effectively inhibiting the overactivation of the HPA axis and achieving rapid suppression of acute stress. In contrast, Comparative Example 1, lacking outer layer metabolites and with significant loss of probiotics in the stomach, and Comparative Example 2, completely lacking outer layer metabolites, both failed to achieve rapid efficacy.

[0182] 3. Testing of physiological indicators of mood regulation in humanized gut microbiota mice: Germ-free mice (GF mice) aged 6-8 weeks or older were used to clear the in situ intestinal flora by gavage for 14 consecutive days using a combination of antibiotics (ABX, containing ampicillin, vancomycin, etc.). Fecal samples from human donors with obvious anxiety / depression symptoms (assessed by the HAM-A / HAM-D scale) were prepared into a 10% suspension and transplanted into recipient mice by gavage for 3 consecutive days. One week after the flora reached equilibration, a chronic unpredictable stress (CUMS) model was established in humanized mice for 21 days.

[0183] Mice were divided into an example group, a control group, and a model group (CK). Mice were administered the drug 200 mg / kg by gavage daily for 14 consecutive days. The model group (CK) was administered an equal volume of physiological saline by gavage.

[0184] Fourteen days later, total DNA was extracted from feces collected on day 14 and measured by qPCR. Anaerobutyricum soehngenii The absolute abundance was used to assess the colonization ability of the core probiotics.

[0185] Fourteen days later, high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS) was used to quantitatively analyze 5-HT, GABA, and dopamine metabolites (DOPAC) in the hippocampus to assess central neurotransmitter levels. Fourteen days later, mouse serum was collected, and serum levels of corticosterone (CORT) and adrenocorticotropic hormone (ACTH), reflecting HPA axis activity, were measured by ELISA to assess HPA axis stress load levels. Simultaneously, serum LPS levels were measured by ELISA to assess key indicators of intestinal mucosal permeability and systemic low-grade inflammation.

[0186] The test results are shown in Table 3.

[0187] Table 3. Physiological parameters of humanized gut microbiota-induced stress mice after 14 days of microcapsule administration. As can be seen from the physiological index test results in Table 3, the microcapsules prepared in Examples 1-3 showed significant improvement in many core indicators.

[0188] In terms of colonization ability, the abundance of the core microbiota in the example group was significantly higher than that in Comparative Examples 1 and 2, and much higher than that in Comparative Example 3, which confirmed the protective effect of the three-layer structure on probiotics, the promoting effect of the outer metabolites on colonization, and the key role of the core pectin in colon-targeted release and efficient colonization.

[0189] Regarding barrier repair and stress regulation, the serum LPS concentration, ACTH, and corticosterone levels in the example group were significantly lower than those in the model group and the control group, demonstrating that the combination effectively repaired the damaged intestinal barrier and blocked the neuroinflammation caused by endotoxins entering the bloodstream at the source. Simultaneously, the synchronous decline in ACTH and corticosterone levels indicates that the product inhibited the overactivation of the HPA axis, thereby alleviating the body's stress state.

[0190] Regarding neurotransmitter improvement, Examples 1 and 3 showed significant effects in enhancing 5-HT, while Example 2 demonstrated a clear advantage in enhancing DOPAC, reflecting the specific regulatory mechanisms of different sugar-bacteria combinations.

[0191] Furthermore, the hippocampal GABA levels in each of the example groups were significantly higher than those in the control groups, confirming the synergistic effect of yeast protein wall material and core material components in improving anxiety and depression-like behaviors. In addition, the colon-targeted release of pectin from the probiotic powder core plays an important role in maintaining high levels of neurotransmitters.

[0192] 4. Testing of core metabolites from the synergistic fermentation of specific functional oligosaccharides and probiotics: Prepare a carbon-limited anaerobic fermentation basal medium that does not contain carbon sources to eliminate interference from non-target carbon sources.

[0193] The microcapsule products prepared in Examples 1-3 and Comparative Examples 1-3 were inoculated into the above-mentioned fermentation medium and placed in an anaerobic workstation (85% N2, 10% H2, 5% CO2) at 37°C for continuous constant temperature fermentation for 48 hours.

[0194] After fermentation, the supernatant of each group of fermentation broth was collected by centrifugation. The concentrations of butyric acid, propionic acid, 5-hydroxytryptamine, phenyllactic acid, indoleacetic acid, and indolelactic acid in the fermentation broth were determined by gas chromatography-mass spectrometry (GC-MS) to evaluate the levels of metabolites produced by different formulations.

[0195] The test results are shown in Table 4.

[0196] Table 4. Metabolites after 48 hours of in vitro fermentation As shown in Table 4, the production of the core metabolites (propionic acid, butyric acid, 5-hydroxytryptamine, phenyllactic acid, indoleacetic acid, and indolelacic acid) in Examples 1-3 was significantly higher than that in the comparative examples.

[0197] Regarding short-chain fatty acids, the butyric acid production in Examples 1 and 3 was significantly higher than that in the other pairs, demonstrating the synergistic promoting effect of the five functional oligosaccharides on the acid production capacity of the three bacteria; the propionic acid production in Example 2 was significantly higher than that in the other pairs, indicating that the bacterial strain ratio and oligosaccharide composition have a differentiated regulatory effect on acid production.

[0198] Regarding neuroactive metabolites, the production of 5-hydroxytryptamine, phenyllactic acid, indoleacetic acid, and indolelacic acid in the Example Group was significantly higher than that in the Comparative Examples. Among them, the production of all metabolites in Comparative Example 3 (without inner pectin) was the lowest. Due to the lack of low-esterified amidated pectin, the probiotics were released prematurely in the simulated small intestine stage and could not effectively reach the colonic fermentation system in the form of live bacteria. This further confirmed the key role of core pectin in colonic targeted release and effective colonization.

[0199] The above test results show that, through the screening and rational design of combinations of metabolites and functional oligosaccharides, this invention not only enhances the efficiency of short-chain fatty acid production through sugar-bacterial co-fermentation, but also simultaneously promotes the generation of various neuroactive metabolites in the tryptophan metabolic pathway, thereby jointly playing a role in regulating gut-brain axis function from two levels: intestinal barrier repair and neurotransmitter regulation.

[0200] In summary, this invention has produced a microcapsule of functional oligosaccharides, probiotics, and their metabolites for improving mood. The microcapsule of this invention is based on a specific synergistic combination of probiotics and functional oligosaccharides, a three-layer encapsulation structure, and a clever combination of core material components and a synergistic combination of sugars and bacteria. It balances high probiotic survival rate, rapid onset of action, and precise regulation of mood-related indicators along the gut-brain axis, providing a novel option for mood-regulating microcapsules for sub-healthy individuals experiencing emotional imbalance and stress.

[0201] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. A microcapsule based on functional oligosaccharides, probiotics, and their metabolites, characterized in that, The microcapsule consists of, from the inside out, a probiotic powder core, a functional oligosaccharide-yeast protein combination coating, and a functional small molecule metabolite complex enteric coating. The probiotic powder core is prepared by using probiotic freeze-dried powder, low-ester amidated pectin and sodium alginate in a mass ratio of (15~25):(10~16):(1~2); The probiotic freeze-dried powder is selected from Anaerobutyricum soehngenii , Coprococcus comes , Lachnoclostridium phocaeense One or more of the following, the total colony count in the probiotic freeze-dried powder is not less than 1.0 × 10⁻⁶. 8 CFU / g; The functional oligosaccharide-yeast protein combination coating is prepared by mixing functional oligosaccharides and yeast protein at a mass ratio of (15~25): (10~15); The functional oligosaccharide is one or more of the following: neo-agnatase, 2'-FL, xylotriose, chitobiose, and maltotetraose. The functional small molecule metabolite complex enteric coating is prepared by using functional small molecule metabolite complex lyophilized powder, pH-sensitive enteric material and plasticizer in a mass ratio of (10~20): (10~16): (1~4); The lyophilized powder of the functional small molecule metabolite complex exists in the form of a functional small molecule metabolite-resistant dextrin complex, wherein the functional small molecule metabolite is one or more of propionic acid, butyric acid, 3,4-dihydroxyphenylacetic acid, 5-hydroxytryptamine, phenyllactic acid, indoleacetic acid, and indolelactic acid.

2. The microcapsule based on functional oligosaccharides, probiotics, and their metabolites according to claim 1, characterized in that, The thickness of the functional oligosaccharide-yeast protein combination coating is 10-15 μm, and the thickness of the functional small molecule metabolite complex enteric coating is 8-14 μm. The overall diameter of the microcapsule is 120~180 μm; The probiotic powder core, the functional oligosaccharide-yeast protein combination coating, and the functional small molecule metabolite complex enteric coating account for 45%~55%, 30%~35%, and 15%~25% of the total mass of the microcapsules, respectively.

3. The microcapsule based on functional oligosaccharides, probiotics, and their metabolites according to claim 1, characterized in that, The low-ester amidated pectin has an esterification degree of no more than 50%, an amidation degree of 20% to 35%, and can be specifically degraded by pectinase secreted by colonic flora. The probiotic freeze-dried powder is Anaerobutyricum soehngenii , Coprococcus comes and Lachnoclostridium phocaeense The compound has a mass ratio of (15~25): (10~15): (5~10).

4. The microcapsule based on functional oligosaccharides, probiotics, and their metabolites according to claim 1, characterized in that, The probiotic freeze-dried powder is prepared by the following method: The target strain was inoculated onto a solid culture medium and cultured under anaerobic conditions at 37 °C for 48–72 hours. Single colonies were then picked for purification culture. The purified single colonies were inoculated onto a liquid culture medium and cultured anaerobically at 37 °C for 24–36 hours to obtain the seed culture. Inoculate the seed culture into the fermenter at a rate of 5%–10%, and ferment at 37 °C under anaerobic conditions for 24–48 hours until the viable probiotic count reaches 1.0 × 10⁻⁶. 8 ~1.0×10 9 CFU / mL, centrifuge to collect bacterial sludge; The bacterial sludge and pre-cooled compound freeze-drying protectant were mixed evenly at a mass ratio of 1: (2~3), pre-frozen, freeze-dried, ground, pulverized, and sieved to obtain probiotic freeze-dried powder. The composite freeze-drying protectant is composed of the following raw materials in the indicated mass percentages: 10%~20% skim milk powder, 5%~10% trehalose, 0.8%~1.2% monosodium glutamate, 0.4%~0.6% cysteine ​​hydrochloride, and the remainder being sterile water.

5. A microcapsule based on functional oligosaccharides, probiotics, and their metabolites according to claim 1, characterized in that, The functional oligosaccharide is a compound of neo-agnatase, 2'-FL, xylotriose, chitobiose, and maltotetraose, with a mass ratio of (15~35):(8~20):(5~20):(3~5):(3~15); The yeast protein is a protein hydrolysate obtained by controlled enzymatic hydrolysis of Saccharomyces cerevisiae, and its peptide molecular weight is mainly distributed between 5000 and 30000 Da.

6. A microcapsule based on functional oligosaccharides, probiotics, and their metabolites according to claim 1, characterized in that, The resistant dextrin is one or more of the following: high-branched corn starch-based water-soluble resistant dextrin with a DE value of 3-6, esterified resistant dextrin, and cassava-based resistant dextrin with a DE value of 6-10. The pH-sensitive enteric material is Eudragit L30D-55 aqueous dispersion; The plasticizer is triethyl citrate; The mass ratio of the functional small molecule metabolite to resistant dextrin is 1:(2~4).

7. A microcapsule based on functional oligosaccharides, probiotics, and their metabolites according to claim 1, characterized in that, The functional small molecule metabolite not complexed with resistant dextrin was prepared by the following method: Probiotics were inoculated into a fermentation medium containing functional oligosaccharides at a total inoculation rate of 5% to 10%, with the amount of functional oligosaccharides added being 2% to 5% of the volume of the fermentation medium. Fermentation was carried out at 37 ℃, pH 6.5 to 7.0, under anaerobic conditions for 48 to 72 hours, followed by centrifugation to collect the supernatant. The supernatant was concentrated to a solids content of 20% to 30%, pre-frozen, freeze-dried, ground, pulverized, and sieved to obtain functional small molecule metabolites.

8. A method for preparing microcapsules based on functional oligosaccharides, probiotics, and their metabolites as described in any one of claims 1-7, characterized in that, The preparation method includes the following steps: S1: Mix probiotic freeze-dried powder, low-ester amidated pectin, and sodium alginate evenly, add water and knead into a soft mass, sieve to obtain wet granules; dry the wet granules in a fluidized bed to obtain the probiotic powder core; S2: Prepare a coating solution with a total solid content of 8%~10% by mixing yeast protein and functional oligosaccharides in a mass ratio; put the probiotic powder core obtained in S1 into a fluidized bed coating machine, spray the functional oligosaccharide-yeast protein combined coating solution onto the surface of the probiotic powder core to form a coating, and continue fluidized drying to obtain double-layer particles. S3: Dissolve the pH-sensitive enteric material, the lyophilized powder of the functional small molecule metabolite complex, and the plasticizer in water to prepare a coating solution with a total solid content of 15%~20%; put the bilayer particles obtained in S2 into a fluidized bed coating machine, spray the enteric coating solution of the functional small molecule metabolite complex onto the surface of the bilayer particles to form a coating, continue fluidized drying, and finally obtain the microcapsules.

9. The method for preparing microcapsules based on functional oligosaccharides, probiotics, and their metabolites according to claim 8, characterized in that, In step S1, the wet particles have a particle size of 90~120 μm and the drying temperature is 35~38 ℃; In step S2, the inlet air temperature of the fluidized bed coating machine is 38~40 ℃, the outlet air temperature is 30~35 ℃, the atomization pressure is 0.1~0.15 MPa, the spraying rate is 1~2 mL / min, and the diameter of the double-layer particles is 120~140 μm. In step S3, the inlet air temperature of the fluidized bed coating machine is 35~38 ℃, the outlet air temperature is 28~32 ℃, the atomization pressure is 0.1~0.12 MPa, and the spraying rate is 0.5~1 mL / min.

10. The use of a microcapsule based on functional oligosaccharides, probiotics, and their metabolites as described in any one of claims 1-7 in the preparation of a pharmaceutical or functional food, characterized in that, The functional foods mentioned are powders or solid beverages used to regulate gut microbiota, improve mood, or as dietary supplements.

Citation Information

Patent Citations

  • A galactooligosaccharide composition for use in preventing or treating cognitive dysfunction and emotional disturbances in neuropsychiatry illnesses or ageing

    CN105073120A

  • Oral compound strain fermentation product and application thereof

    CN114304513A

  • Anti-anxiety and anti-depression compound probiotics and application thereof

    CN117887646A